Product Description
Investigational SARS-CoV-2 mRNA Vaccine (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04449276)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CureVac
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Belgium, Colombia, Dominican Republic, Germany, Mexico, Netherlands, Panama, Peru, Spain
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: COVID-19|Severe Acute Respiratory Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CV-NCOV-004 | P3 |
Completed |
COVID-19 |
2022-06-10 |
|
| Germany | P3 |
Completed |
Severe Acute Respiratory Syndrome|COVID-19 |
2022-06-08 |
|
| Immunogenicity and Safety of CVnCoV in Adults | P3 |
Completed |
COVID-19 |
2022-06-08 |
|
| HERALD | P3 |
Completed |
COVID-19 |
2022-06-03 |